Blog | HemaCare

CTLA-4 Discovery in Dendritic Cells Opens New Doors for Cancer Immunotherapy

Jul 18, 2016 1:00:18 PM / by Karina Palomares posted in ipilimumab, Cancer Immunology, cancer immunotherapy, CD8+ T cells, CTLA-4


New research suggests that dendritic cells produce and release CTLA-4, which typically inhibits anticancer responses.

Cancer immunotherapy strategies have made it increasingly evident that the immune system plays an integral role in managing and destroying cancer. Nevertheless, many mechanisms of immune suppression exist that may inhibit antitumor immunity. Recently, strategies that implement antibodies directed against negative immunologic regulators have demonstrated significant success. Cytotoxic T-lymphocyte-associate protein-4 (CTLA-4) was the first immunologic checkpoint to be clinically targeted, by the cancer immunotherapeutic ipilimumab, an FDA-approved drug to treat melanoma. After T-cell activation, CTLA-4 is upregulated on the cell surface where it functions to downregulate T cell function. Ipilimumab binds to CTLA-4 on T cells, which blocks the inhibitory signals and enhances anti-cancer immune responses.
Read More

Cancer Drug Targeting T cells: The CTLA-4 Checkpoint Inhibitor

Mar 23, 2015 1:00:53 PM / by Daisy posted in cancer drug, cancer immunotherapy, checkpoint inhibitors, CTLA-4, PD-1, research


Immune checkpoints modulate either the activation or downplay of T cells but can be manipulated by cancer cells. We can strike back with newer drugs.

Read More

Subscribe Here!

Posts by Topic

see all

Recent Posts